Tehran University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share this content! On (X network) By
Clinical Outcomes of Kidney Recipients With Covid-19 (Covid-19 in Kidney Recipients) Publisher Pubmed



Hajibaratali B1 ; Amini H2 ; Dalili N3 ; Ziaie S2 ; Anvari S1 ; Keykha E4 ; Rezaee M5, 6 ; Samavat S3
Authors
Show Affiliations
Authors Affiliations
  1. 1. Department of Cardiology, Labbafinejad Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran
  2. 2. Department of Clinical Pharmacy, School of Pharmacy, Shahid Beheshti University of Medical Sciences, Tehran, Iran
  3. 3. Chronic Kidney Disease Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran
  4. 4. Department of Internal Medicine, Labbafinejad Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran
  5. 5. Medical Student Research Committee, School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran
  6. 6. Non-Communicable Disease Research Center, Endocrinology and Metabolism Population Sciences Institute, Tehran University of Medical Sciences, Tehran, Iran

Source: Transplant Immunology Published:2023


Abstract

Introduction: The coronavirus disease 2019 (COVID-19) pandemic has caused significant mortality since late 2019. Patients undergoing kidney transplantation (KT) are prone to COVID-19 due to immunosuppressive drug use and various comorbidities such as hypertension and diabetes. Methods: One hundred thirty-three KT recipients with COVID-19 were included in this retrospective cohort study. Hospital mortality was considered a primary outcome, while acute kidney injury (AKI) was considered a secondary outcome. Demographic information, maintenance immunosuppression, medical history, laboratory information, and echocardiographic and electrocardiography results of patients were recorded. Patients were also followed for 2 months post-discharge for post-COVID-19 symptoms, readmission, and transplant function. Results: Regarding the primary outcome of the 133 patients, 13 died and 120 survived. The deceased patients were significantly older (median age, 64 vs. 50.5 years; p = 0.04) and had a significantly higher median serum creatinine level (p = 0.002) and lower median glomerular filtration rate (p = 0.010) than patients who survived. The incidence of AKI was 47.3%, more common in deceased patients (p = 0.038) than in patients who survived. Troponin levels were significantly higher in deceased patients and those with AKI (p = 0.0004 and p = 0.039, respectively) than in patients who survived and those without AKI. A multivariable Cox regression analysis revealed that older age (adjusted hazard ratio, 1.13; 95% confidence interval, 1.01–1.27) and AKI (adjusted hazard ratio, 3.43; 95% confidence interval, 1.34–8.79) were associated with in-hospital mortality. Conclusion: In conclusion, kidney recipients with COVID-19 had a higher mortality rate than the general population, with a higher prevalence in older individuals and those who experienced AKI during hospitalization than in patients who survived and those without AKI. © 2022
Other Related Docs
10. Covid-19 Infection in Kidney Transplant Recipients From a Single Center in Iran, Experimental and Clinical Transplantation (2022)
17. Critical Complications of Covid-19: A Descriptive Meta-Analysis Study, Reviews in Cardiovascular Medicine (2020)